Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors

Laboratory Investigation

Volumn 91, Issue 7, 2011, Pages 1068-1078

  Mao, Xing Gang ^a   Yan, Ming ^a   Xue, Xiao Yan ^b   Zhang, Xiang ^a   Ren, Hong Gang ^c   Guo, Geng ^a,d   Wang, Peng ^a   Zhang, Wei ^a   Huo, Jun Li ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Department of Neurosurgery   (China)

^d SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

cancer stem cell; CD133; HIF1a; HIF2 ; hypoxia

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PROTEIN ZNF217; SMALL INTERFERING RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; CELL HYPOXIA; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; BRAIN NEOPLASMS; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASTIC STEM CELLS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 79959728686     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.56     Document Type: Article

References (52)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-123.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996. (Pubitemid 40349501)
3. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401. (Pubitemid 39551674)
4. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648. (Pubitemid 24067706)
5. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer 2006;6:425-436.
6. Mao XG, Zhang X, Zhen HN. Progress on potential strategies to target brain tumor stem cells. Cell Mol Neurobiol 2009;29:141-155.
7. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760. (Pubitemid 44949604)
8. Bar EE, Lin A, Mahairaki V, et al. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 2010;177:1491-1502.
9. Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009;15:501-513.
10. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82. (Pubitemid 46054518)
11. Seidel S, Garvalov BK, Wirta V, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010;133:983-995.
12. Mazumdar J, O'Brien WT, Johnson RS, et al. O(2) regulates stem cells through Wnt/beta-catenin signalling. Nat Cell Biol 2010;12:1007-1013.
13. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465-472. (Pubitemid 46660978)
14. Platet N, Liu SY, Atifi ME, et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007;258: 286-290. (Pubitemid 350110377)
15. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008;8:967-975.
16. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441:437-443. (Pubitemid 44050138)
17. Semenza GL. Life with oxygen. Science 2007;318:62-64. (Pubitemid 47538005)
18. Kaelin Jr WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393-402. (Pubitemid 351681994)
19. Mendez O, Zavadil J, Esencay M, et al. Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer 2010;9:133.
20. Krig SR, Miller JK, Frietze S. et al. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene 2010;29:5500-5510.
21. Sun G, Zhou J, Yin A, et al. Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line. Int J Oncol 2008;32:1065-1071.
22. Quinlan KG, Verger A, Yaswen P, et al. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. Biochim Biophys Acta 2007;1775:333-340. (Pubitemid 46908864)
23. Li P, Maines-Bandiera S, Kuo WL, et al. Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. Int J Cancer 2007;120:1863-1873. (Pubitemid 46418361)
24. Nonet GH, Stampfer MR, Chin K, et al. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res 2001;61:1250-1254. (Pubitemid 34292535)
25. Collins C, Rommens JM, Kowbel D, et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci USA 1998;95:8703-8708. (Pubitemid 28350552)
26. Krig SR, Jin VX, Bieda MC, et al. Identification of genes directly regulated by the oncogene ZNF217 using chromatin immunoprecipitation (ChIP)-chip assays. J Biol Chem 2007;282: 9703-9712. (Pubitemid 47104577)
27. Cowger JJ, Zhao Q, Isovic M, et al. Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence. Oncogene 2007;26:3378-3386. (Pubitemid 46788885)
28. Mao XG, Zhang X, Xue XY, et al. Brain tumor stem-like cells identified by neural stem cell marker CD15. Transl Oncol 2009;2:247-257.
29. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068.
30. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391-403. (Pubitemid 43668737)
31. Mao XG, Guo G, Wang P, et al. Maintenance of critical properties of brain tumor stem like cells after cryopreservation. Cell Mol Neurobiol 2010;30:775-786.
32. Soeda A, Park M, Lee D, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009;28:3949-3959.
33. Heddleston JM, Li Z, McLendon RE, et al. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009;8:3274-3284.
34. Jordan CT. Cancer stem cells: controversial or just misunderstood? Cell Stem Cell 2009;4:203-205.
35. Chen R, Nishimura MC, Bumbaca SM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010;17: 362-375.
36. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(+) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007;67:4010-4015. (Pubitemid 46815044)
37. Son MJ, Woolard K, Nam DH, et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009;4:440-452.
38. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
39. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-173. (Pubitemid 43357943)
40. Lottaz C, Beier D, Meyer K, et al. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 2010;70:2030-2040.
41. Zheng H, Ying H, Wiedemeyer R, et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell 2010;17:497-509.
42. Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006;66:7445-7452. (Pubitemid 44289197)
43. Bar EE, Chaudhry A, Lin A, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007;25:2524-2533. (Pubitemid 47582744)
44. Facchino S, Abdouh M, Chatoo W, et al. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci 2010;30: 10096-10111.
45. Abdouh M, Facchino S, Chatoo W, et al. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 2009;29: 8884-8896.
46. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumourinitiating cells. Nature 2006;444:761-765. (Pubitemid 44949605)
47. Mole DR, Blancher C, Copley RR, et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 2009;284:16767-16775.
48. Quinlan KG, Nardini M, Verger A, et al. Specific recognition of ZNF217 and other zinc finger proteins at a surface groove of C-terminal binding proteins. Mol Cell Biol 2006;26:8159-8172. (Pubitemid 44631013)
49. Shi YJ, Matson C, Lan F, et al. Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell 2005;19:857-864. (Pubitemid 41316679)
50. Chinnadurai G. Transcriptional regulation by C-terminal binding proteins. Int J Biochem Cell Biol 2007;39:1593-1607. (Pubitemid 47088308)
51. Banck MS, Li S, Nishio H, et al. The ZNF217 oncogene is a candidate organizer of repressive histone modifiers. Epigenetics 2009;4:100-106.
52. Huang G, Krig S, Kowbel D, et al. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Hum Mol Genet 2005;14:3219-3225. (Pubitemid 41631296)